Impacts of intravitreal anti-VEGF therapy on retinal anatomy and neurophysiology in diabetic macular edema

被引:5
|
作者
Yozgat, Zubeyir [1 ]
Dogan, Mustafa [1 ]
Sabaner, Mehmet Cem [1 ]
Gobeka, Hamidu Hamisi [2 ]
Yazgan Akpolat, Serpil [3 ]
机构
[1] Afyonkarahisar Hlth Sci Univ, Afyon, Turkey
[2] Ibrahim Cecen Univ Agri, Agri Merkez, Turkey
[3] Malatya Inonu Univ, Malatya, Turkey
关键词
Aflibercept; Diabetic macular edema; Fundus fluorescein angiography; Microperimetry; Multifocal electroretinography; Optical coherence tomography;
D O I
10.1007/s10792-021-01737-w
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose To evaluate anatomical and neuroretinal functional aspects in patients with diabetic macular edema (DME) after intravitreal anti-vascular endothelial growth factor (VEGF) therapy, in particular aflibercept. Materials and methods This prospective single-centered interventional study was performed at Afyonkarahisar Health Science University Faculty of Medicine, Department of Ophthalmology, where 32 eyes of 32 patients with DME were investigated. All patients received five intravitreal aflibercept injections on a monthly basis and were followed up for >= 6 months. After a comprehensive ophthalmological examination, including the measurements of visual acuity and intraocular pressure, and an antero-posterior segment slit-lamp biomicroscopy before and after full pupil dilation, fundus fluorescein angiography and optical coherence tomography were performed at baseline and during the third and sixth months post-therapy. Microperimetry and multifocal electroretinography were also performed at baseline and during the sixth months. Results Mean visual acuity increased from 0.73 to 0.57 and 0.33 logarithm of the minimum angle of resolution (logMAR) during the third and sixth months, respectively (p < 0.001). Changes in intraocular pressure were not statistically significant (p = 0.472). There was statistically significantly decreased mean central macular thickness from 390.2 mu m to 242.6 and 289.7 mu m during the third and sixth months, respectively (p < 0.001). Significantly improved fixation patterns during the sixth month, along with significantly increased macular sensitivity from 8.2 to 14.2 dB (p < 0.001) and significantly decreased local deficit from - 10.3 to 5.5 dB (p < 0.001) were observed. Further, there was a significantly increased N1 amplitude in the first ring and significantly increased P1 amplitude in all rings (p for each parameter < 0.05). There was also significantly decreased N1 wave implicit time in all rings and significantly decreased P1 wave in the second, third, fourth and fifth rings (p for each parameter < 0.05). Conclusions Patients with DME showed profound improvement in the retinal neurophysiological function, which was also accompanied by anatomical and ultrastructural integrity recovery after intravitreal aflibercept therapy. In the pathogenesis of DME, the influence of neurodegeneration has been increasingly gaining significant attention. Consequently, the need to assess neurophysiological effects of anti-VEGF therapy using a variety of diagnostic measures like electrophysiological studies and multimodal imaging technologies is undeniably growing.
引用
收藏
页码:1783 / 1798
页数:16
相关论文
共 50 条
  • [31] Relationship Between Macular Thickness and Visual Acuity in the Treatment of Diabetic Macular Edema With Anti-VEGF Therapy: Systematic Review
    Wang, Patrick
    Hu, Zoe
    Hou, Maggie
    Norman, Patrick A. A.
    Chin, Eric K. K.
    Almeida, David R. P.
    JOURNAL OF VITREORETINAL DISEASES, 2023, 7 (01) : 57 - 64
  • [32] Evaluation of outer retinal tubulations in diabetic macular edema underwent anti-VEGF treatment
    Xiao-Li Huang
    Yan-Ping Song
    Qin Ding
    Xiao Chen
    Ling Hong
    International Journal of Ophthalmology, 2019, (03) : 442 - 450
  • [33] The effect of intravitreal anti-VEGF injections on choroidal vascular index in patients with diabetic macular edema
    Toprak, Aydin
    Koc, Hakan
    Alpay, Atilla
    Ugurbas, Suat Hayri
    CUTANEOUS AND OCULAR TOXICOLOGY, 2024, 43 (03) : 204 - 210
  • [34] Dexamethasone Implant in Patients with Diabetic Macular Edema Resistant to Anti-VEGF Therapy
    Nalcaci, Serhad
    Akkin, Cezmi
    Afrashi, Filiz
    TURK OFTALMOLOJI DERGISI-TURKISH JOURNAL OF OPHTHALMOLOGY, 2019, 49 (02): : 73 - 77
  • [35] A real-world study for timely assessing the diabetic macular edema refractory to intravitreal anti-VEGF treatment
    Hsieh, Tsung-Cheng
    Deng, Guang-Hong
    Chang, Yung-Ching
    Chang, Fang-Ling
    He, Ming-Shan
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [36] Maintenance of Vision Needed to Drive after Intravitreal Anti-VEGF Therapy in Patients with Neovascular Age-related Macular Degeneration and Diabetic Macular Edema
    Emami-Naeini, Parisa
    Garmo, Vincent
    Boucher, Nick
    Fernando, Rusirini
    Menezes, Alicia
    OPHTHALMOLOGY RETINA, 2024, 8 (04): : 388 - 398
  • [37] Anti-VEGF Monotherapy vs Anti-VEGF and Steroid Combination Therapy for Diabetic Macular Edema: A Meta-analysis
    Grad, Justin
    Hatamnejad, Amin
    Dadak, Rohan
    Sodhi, Simrat
    Pattathil, Niveditha
    Choudhry, Netan
    JOURNAL OF VITREORETINAL DISEASES, 2025, 9 (01) : 70 - 83
  • [38] Phacoemulsification surgery in patients with diabetic macular edema: should intravitreal anti-VEGF therapy be performed before or simultaneously with surgery?
    Guven, Yusuf Ziya
    Isik, Mehmed Ugur
    Ilguey, Serdar
    Yozgat, Zubeyir
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2025, 18 (04) : 637 - 641
  • [39] The Impact of Laboratory Findings and Optical Coherence Tomography Biomarkers on Response to Intravitreal Anti-VEGF Treatment in Patients with Diabetic Macular Edema
    Chatziralli, Irini
    Dimitriou, Eleni
    Lambadiari, Vaia
    Kazantzis, Dimitrios
    Kapsis, Petros
    Theodossiadis, George
    Theodossiadis, Panagiotis
    Sergentanis, Theodoros N.
    SEMINARS IN OPHTHALMOLOGY, 2022, 37 (05) : 668 - 675
  • [40] Risk of Systemic Adverse Events Associated with Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice
    Maloney, Maya H.
    Schilz, Stephanie R.
    Herrin, Jeph
    Sangaralingham, Lindsey R.
    Shah, Nilay D.
    Barkmeier, Andrew J.
    OPHTHALMOLOGY, 2019, 126 (07) : 1007 - 1015